Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, June 2, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company…

Related Keywords

China ,Tongji ,Sichuan ,Suzhou ,Jiangsu ,Rhui Zhou ,Guangdong ,United States ,Hong Kong ,Shanghai ,Taiwan ,Macau ,American ,Chinese ,Sanofi Incyte ,Eli Lilly ,Wei Li ,Innovent Biologics ,Caicun Zhou ,China National Medical Products Administration ,Md Anderson Cancer Center ,Drug Administration ,National Medical Products Administration ,Linkedin ,Innovent Or Company ,Department Of Oncology At Shanghai East Hospital ,Tongji University ,Innovent Biologics Inc ,American Society Of Clinical Oncology ,Clinical Oncology ,Drug Evaluation ,Principal Investigator ,Shanghai East Hospital ,Senior Vice President ,Breakthrough Therapy Designations ,Priority Review Designations ,New Drug Applications ,Anheart Therapeutics ,Nuvation Bio ,Greater China ,Study Results ,Chinese Patients ,Non Small Cell Lung Cancer ,Medical Oncology ,Non Small Cell ,